Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strong financial performance and optimistic future guidance, particularly with WAKIX's blockbuster revenue projection and robust pipeline advancements. The Q&A session reveals management's strategic focus on expanding CNS indications and protecting IP, despite some uncertainties in litigation and business development. The market cap suggests moderate sensitivity to news, and the overall sentiment is positive, driven by promising product developments and strategic plans. The company's efforts to address analyst concerns and legal challenges indicate a proactive approach, supporting a positive stock price movement prediction.
Key Financial Performance
Net Product Revenue $215.4 million in Q1 2026, up 17% from $184.7 million in Q1 2025. The increase reflects strong demand for WAKIX, offset by market access headwinds typically observed in Q1.
Average Number of Patients Approximately 8,500 in Q1 2026, exiting the quarter with 8,600 patients on WAKIX. This is in a market of 80,000 diagnosed narcolepsy patients, indicating significant growth potential.
Cost of Goods Sold (COGS) 20.7% of net sales in Q1 2026, up from 17.3% in Q1 2025. The increase was driven by new royalties related to the Novitium license agreement.
Total Operating Expenses $133.6 million in Q1 2026, up from $96.5 million in Q1 2025. The increase reflects investments in R&D, commercialization of WAKIX, and upfront licensing fees of $32 million related to the amorphous license agreements.
GAAP Net Income $32.5 million or $0.55 per share in Q1 2026, compared to $45.6 million or $0.78 per share in Q1 2025. The decrease was due to $0.45 per share in costs related to the in-license of the amorphous form of pitolisant.
Cash and Cash Equivalents $870.5 million at the end of Q1 2026. Cash flow generation was impacted by licensing fees, reduction in accrued expenses, and modest debt reduction.
Debt $160 million at the end of Q1 2026, with plans for reaccelerated cash flow generation in the coming quarters.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
WAKIX Growth: WAKIX achieved $215.4 million in net sales in Q1 2026, a 17% year-over-year growth. The product has approximately 8,600 patients, with significant market opportunity remaining in a market of 80,000 diagnosed narcolepsy patients.
Pitolisant GR: Pitolisant GR is on track for NDA submission in Q2 2026, with a target PDUFA date in Q1 2027. It is designed to reduce GI side effects and allows patients to start at a therapeutic dose without titration.
Pitolisant HD: Pitolisant HD is in two Phase 3 trials targeting narcolepsy and idiopathic hypersomnia, with top-line data expected in 2027 and a target PDUFA date in 2028. It aims to address fatigue in narcolepsy and sleep inertia in IH.
BP-205: BP-205, a potential best-in-class Orexin-2 agonist, is progressing in Phase 1 trials with data expected mid-2026. It targets central disorders of hypersomnolence and broader neuropsych indications.
Market Expansion for WAKIX: The company expanded its field team by 20% and launched initiatives like an online portal and improved reimbursement processes to enhance market penetration.
Financial Performance: Net revenues reached $215.4 million in Q1 2026, a 17% increase from the prior year. Operating expenses grew due to R&D and commercialization investments.
Cost Management: Operating expenses included $32 million in licensing fees for new development opportunities, with adjusted expenses up by around 5%.
Intellectual Property Protection: The company has a multilayered IP strategy for the pitolisant franchise, extending exclusivity into the 2030s and potentially the 2040s.
Business Development: With $870 million in cash, the company is focusing on acquiring assets with revenue potential in the 2028-2032 timeframe, prioritizing Phase 3 or on-market assets in CNS-related areas.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Access Headwinds: Higher level of plan changes, plan switching by consumers, and higher premium increases observed in Q1 2026, which can delay patient starts and impact revenue growth.
ANDA Litigation: Ongoing legal proceedings with AET Pharma U.S. and Sandoz regarding patent infringement, which could impact the exclusivity and revenue of the pitolisant franchise.
Regulatory and Development Risks: Potential delays or challenges in regulatory approvals for pipeline products such as Pitolisant GR, Pitolisant HD, and BP-205, which are critical for future growth.
Pipeline Valuation Risk: Current market valuation does not reflect the strength of the pipeline, particularly BP-205, which could affect investor confidence and funding.
Supply Chain and Cost Management: Increase in cost of goods sold due to new royalties related to the Novitium license agreement, which could pressure margins.
Business Development Execution: Risk of not successfully deploying cash into business development opportunities to enhance revenues in the 2028-2032 timeframe.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company reiterated its full-year net revenue guidance of $1 billion to $1.04 billion for 2026.
Pitolisant Franchise Growth: Continued growth of the pitolisant franchise is expected, with a focus on expanding patient numbers in a market of 80,000 diagnosed narcolepsy patients. The company aims to extend the franchise with new formulations such as Pitolisant GR and Pitolisant HD.
Pipeline Development: BP-205, a potential best-in-class Orexin-2 agonist, is on track for Phase 1 SAD PK data in mid-2026 and U.S. IND submission in mid-2026. Pitolisant GR is on track for NDA submission in Q2 2026 with a target PDUFA date in Q1 2027. Pitolisant HD is expected to deliver top-line data in 2027 with a target PDUFA date in 2028.
Business Development: The company is prioritizing business development opportunities with revenue potential in the 2028 to 2032 timeframe, focusing on Phase 3 or market-ready assets in therapeutic areas such as sleep/wake, epilepsy, and rare CNS disorders.
Financial Position: The company has $870.5 million in cash and cash equivalents and plans to deploy this capital for strategic business development opportunities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the roadmap for BP-205 data milestones through 2027, particularly in healthy sleep-deprived volunteers?
A:The company is on track to receive single ascending dose clinical PK data in mid-2023. They are also dosing patients in multiple ascending dose studies and conducting food effect studies, which are important before moving to later clinical stages.
Q:Why not move directly into narcolepsy 1, narcolepsy 2, and IH patients in a Phase 1B study for BP-205?
A:The company believes it is important to establish a dose range in sleep-deprived healthy volunteers first. This step does not add to the timeline as it is conducted in parallel with other studies.
Q:What early-stage work is being done over the next 12-18 months for other indications like mood, ADHD, cognition, and fatigue?
A:The company is conducting preclinical experiments to evaluate the potential of BP-205 in these indications. Data from these experiments will guide future decisions.
Q:What are the next steps in the litigation versus AET Sandoz?
A:The legal process is ongoing, with post-trial briefs expected to be completed by the end of May. A new lawsuit has been filed against AET Sandoz for infringing the 920 amorphous patent, separate from the original ANDA litigation.
Q:How does the higher potency of BP-205 differentiate it in the sleep/wake area compared to other orexins in development?
A:The higher potency allows for lower doses, reducing off-target effects and enabling treatment across all three central disorders of hypersomnolence (NT1, NT2, and IH) with a single compound.
Q:Will BP-205 be developed as a monotherapy or in combination with other treatments?
A:The company is exploring both options. There is scientific rationale for combining BP-205 with pitolisant to potentially realize synergistic effects.
Q:What is the outlook for WAKIX ramp and patient dynamics for the rest of the year?
A:The company expects the rest of the year to follow typical seasonal dynamics, with strong demand and growth consistent with past performance. They are on track to achieve full-year guidance of over $1 billion in net sales.
Q:Why did the company choose to sue on the second lawsuit regarding the Novitium IP?
A:The decision was made after evidence of infringement on the amorphous patent was introduced during the original trial. The lawsuit is part of a multilayered strategy to protect IP.
Q:What is the clinical data for EPX-100 in Dravet syndrome?
A:EPX-100 showed a median seizure reduction of 50% in patients with at least 6 months of exposure. It also demonstrated a favorable safety and tolerability profile, with minimal adverse effects.
Q:What is the company's business development (BD) strategy?
A:The company is focusing on near-term revenue opportunities, particularly in Phase 3 or registrational stage assets, and is open to M&A, licensing, and collaborations. They are targeting areas related to their core competencies, such as sleep/wake, rare CNS diseases, and epilepsy.
Q:What specific PK parameters and tolerability bar would validate BP-205's best-in-class claim?
A:The company will evaluate Tmax, Cmax, AUC, half-life, safety, and tolerability in clinical PK studies to validate BP-205's potential as best-in-class.
Q:What are the plans for the new amorphous form of pitolisant?
A:The amorphous form could enable new modes of oral delivery and a potentially more favorable PK profile for broader CNS indications. The company is optimizing the formulation for a Phase 1 PK study.
Q:What is the trajectory for operating expenses (OpEx) for the rest of the year?
A:Gross margins will be impacted by the Novitium contract and step-up royalties. R&D expenses are expected to increase as trials accelerate, but no substantial increases are expected in other areas.
Q:Why not prioritize other indications for BP-205 instead of competing in the crowded sleep/wake space?
A:The company sees opportunities in both central disorders of hypersomnolence and broader CNS indications. They plan to invest in both areas.
Q:What are the barriers to an at-risk launch by AET in the WAKIX IP situation?
A:The company believes it will prevail in the ANDA case and the new lawsuit. They will use all legal remedies to defend their IP and maintain exclusivity into 2030.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the business development strategy's financial returns, stating only that they aim for substantial returns without elaborating on timelines or specific metrics. Additionally, they did not provide detailed PK parameters or tolerability thresholds for BP-205, only mentioning general metrics like Tmax, Cmax, and AUC.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AET
Anastasiou Chief
BP program
CNS indication
Chief Officer
Dravet Syndrome
IP
NT IH
Novitium patent
Officer Reicin
Orexin agonist
Orexin receptor
PDUFA date
Phase SAD
Phase trial
Pitolisant GR
Pitolisant HD
WAKIX market
access headwind
chemical scaffold
class Orexin
conviction development
debt
development opportunity
form hydrochloride
license
market access
month exclusivity
patent form
pillar value
place
position
quarter
reduction
value creation
HRMY Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary highlights strong financial performance and optimistic future guidance, particularly with WAKIX's blockbuster revenue projection and robust pipeline advancements. The Q&A session reveals management's strategic focus on expanding CNS indications and protecting IP, despite some uncertainties in litigation and business development. The market cap suggests moderate sensitivity to news, and the overall sentiment is positive, driven by promising product developments and strategic plans. The company's efforts to address analyst concerns and legal challenges indicate a proactive approach, supporting a positive stock price movement prediction.
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Neutral4-14
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call reflects strong financial health and strategic growth, with raised revenue guidance and successful product developments. Despite competitive pressures and litigation uncertainties, the company maintains robust cash reserves. The Q&A section highlights a proactive approach to potential risks, with strategic settlements and ongoing R&D investments. The raised revenue guidance and strategic pipeline advancements contribute to a positive outlook, likely resulting in a 2-8% stock price increase.
HRMY Slides
HRMY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
